Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC 12-02)

Next Previous
X
Search
Trial Profile

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC 12-02)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rhenium (186Re) obisbemeda (Primary)
  • Indications Astrocytoma; Diffuse intrinsic pontine glioma; Ependymoma; Glioblastoma; Glioma
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms ReSPECT; ReSPECT-GBM; ReSPECT-TM
  • Sponsors Plus Therapeutics

    • Most Recent Events

    • 02 Jul 2024 According to a Plus Therapeutics media release, the company announced that data from this study will be presented at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer on July 8, 2024 in Newry, Maine.
    • 15 May 2024 According to a Plus Therapeutics media release, company will present update for the Phase 2 ReSPECT-GBM trial for recurrent adult glioblastoma at one of the key neurosurgery or neuro-oncology meetings in late 2024.
    • 15 May 2024 According to a Plus Therapeutics media release, phase 2 trial update from this trial of Rhenium (186Re) obisbemeda (186RNL) in recurrent glioblastoma (rGBM) via convection enhanced delivery (Cm) presented at 2024 NMN (Nuclear Medicine and Neuro-oncology) Symposium (April 26-27).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top